Advertisement

L'Endocrinologo

, Volume 19, Issue 5, pp 247–254 | Cite as

Gestione integrata del tumore della prostata: il ruolo dell’endocrinologo

  • A. Faggiano
  • G. Botti
  • B. Altieri
  • F. Lo Calzo
  • R. Modica
  • M. Gasperi
  • A. Colao
Rassegna
  • 35 Downloads

Sommario

Il carcinoma della prostata (CP) è una patologia di grande interesse endocrinologico sotto diversi aspetti. Dai fattori di rischio, prevalentemente endocrino-metabolici, alle terapie, basate in gran parte sulla soppressione dell’asse gonadico, agli effetti collaterali delle terapie che incidono sul metabolismo, il tessuto osseo, la funzione sessuale, c’è grande necessità di includere l’endocrinologo nel team multidisciplinare del paziente con CP. D’altro lato, la ricerca endocrinologica di base e traslazionale può contribuire alla genotipizzazione molecolare del CP e all’elaborazione di terapie a bersaglio molecolare mirate.

Parole chiave

Carcinoma prostatico Endocrinologia Fattori di rischio Terapia ormonale Terapia a bersaglio molecolare Complicanze endocrine 

Notes

Conflitto di interesse

Gli autori Antongiulio Faggiano, GerardoBotti, Barbara Altieri, Fabio Lo Calzo, Roberta Modica, Maurizio Gasperi e Annamaria Colao dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2018_483_MOESM1_ESM.doc (28 kb)
(DOC 29 kB)
40619_2018_483_MOESM2_ESM.doc (26 kb)
(DOC 27 kB)

Bibliografia

  1. 1.
    Linee Guida AIOM (2017) Carcinoma della prostata. http://www.aiom.it/professionisti/documenti-scientifici/linee-guida. Accessed on 10/10/18
  2. 2.
    Egevad L, Delahunt B, Srigley JR, Samaratunga H (2016) International Society of Urological Pathology (ISUP) grading of prostate cancer—an ISUP consensus on contemporary grading. APMIS 124:433–435 CrossRefGoogle Scholar
  3. 3.
    Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025 CrossRefGoogle Scholar
  4. 4.
    Tomlins SA, Laxman B, Dhanasekaran SM et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448:595–599 CrossRefGoogle Scholar
  5. 5.
    Adamo P, Ladomery MR (2016) The oncogene ERG: a key factor in prostate cancer. Oncogene 35:403–414 CrossRefGoogle Scholar
  6. 6.
    Jaratlerdsiri W, Chan EK, Petersen DC et al. (2017) Next generation mapping reveals novel large genomic rearrangements in prostate cancer. Oncotarget 8:23588–23602 CrossRefGoogle Scholar
  7. 7.
    Du YF, Ou HY, Beverly EA, Chiu CJ (2014) Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clin Interv Aging 9:1963–1980 Google Scholar
  8. 8.
    Crawley D, Chamberlain F, Garmo H et al. (2018) A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience 12:802 CrossRefGoogle Scholar
  9. 9.
    Margel D, Urbach DR, Lipscombe LL et al. (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069–3075 CrossRefGoogle Scholar
  10. 10.
    Golabek T, Bukowczan J, Chlosta P et al. (2014) Obesity and prostate cancer incidence and mortality: a systematic review of prospective cohort studies. Urol Int 92:7–14 CrossRefGoogle Scholar
  11. 11.
    Weiner AB, Kundu SD (2018) Prostate cancer: a contemporary approach to treatment and outcomes. Med Clin North Am 102:215–229 CrossRefGoogle Scholar
  12. 12.
    Hossain MK, Nahar K, Donkor O, Apostolopoulos V (2018) Immune-based therapies for metastatic prostate cancer: an update. Immunotherapy 10:283–298 CrossRefGoogle Scholar
  13. 13.
    Markowitz JN, Fancher KM (2018) Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy 38:357–369 CrossRefGoogle Scholar
  14. 14.
    Tzortzis V, Samarinas M, Zachos I et al. (2017) Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens) 16:115–123 Google Scholar
  15. 15.
    Ricci F, Buzzatti G, Rubagotti A, Boccardo F (2014) Safety of antiandrogen therapy for treating prostate cancer. Expert Opin Drug Saf 13:1483–1499 CrossRefGoogle Scholar
  16. 16.
    Nguyen PL, Alibhai SM, Basaria S et al. (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67:825–836 CrossRefGoogle Scholar
  17. 17.
    Cianferotti L, Bertoldo F, Carini M et al. (2017) The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget 8:75646–75663 CrossRefGoogle Scholar
  18. 18.
    Cukier P, Santini FC, Scaranti M, Hoff AO (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24:T331–T347 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • A. Faggiano
    • 1
  • G. Botti
    • 2
  • B. Altieri
    • 1
  • F. Lo Calzo
    • 1
  • R. Modica
    • 1
  • M. Gasperi
    • 3
  • A. Colao
    • 1
  1. 1.Dipartimento di Medicina Clinica e Chirurgia, UOC EndocrinologiaUniversità Federico II di NapoliNapoliItalia
  2. 2.SC Anatomia Patologica e Citopatologia, Istituto Nazionale dei TumoriIRCCS Fondazione G. PascaleNapoliItalia
  3. 3.Dipartimento di medicina e scienze della salute “V. Tiberio”Università del MoliseCampobassoItalia

Personalised recommendations